KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBIT (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EBIT for 16 consecutive years, with -$92.9 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 152.93% to -$92.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $469.0 million through Dec 2025, down 14.95% year-over-year, with the annual reading at $469.0 million for FY2025, 14.95% down from the prior year.
  • EBIT for Q4 2025 was -$92.9 million at Halozyme Therapeutics, down from $217.9 million in the prior quarter.
  • The five-year high for EBIT was $217.9 million in Q3 2025, with the low at -$92.9 million in Q4 2025.
  • Average EBIT over 5 years is $95.1 million, with a median of $90.7 million recorded in 2021.
  • The sharpest move saw EBIT surged 1674.15% in 2021, then plummeted 152.93% in 2025.
  • Over 5 years, EBIT stood at $56.5 million in 2021, then surged by 31.8% to $74.5 million in 2022, then soared by 35.6% to $101.0 million in 2023, then soared by 73.7% to $175.5 million in 2024, then tumbled by 152.93% to -$92.9 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$92.9 million, $217.9 million, and $202.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.